You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 8,802,103

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,802,103

Title:	Compositions and methods for diagnosing and treating cancer
Abstract:	Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody.
Inventor(s):	Gurney; Austin (San Francisco, CA), Hoey; Timothy (Hillsborough, CA), Satyal; Sanjeev (San Carlos, CA), Fitch Bruhns; Maureen (San Mateo, CA)
Assignee:	OncoMed Pharmaceuticals, Inc. (Redwood City, CA)
Application Number:	12/121,348
Patent Claims:	1. An isolated monoclonal antibody that competes for specific binding to human Jagged 1 with the antibody 64M14. 2. The antibody of claim 1 which is a chimeric antibody. 3. The antibody of claim 1 which is a humanized antibody. 4. The antibody of claim 1 which is a human antibody. 5. A composition comprising the monoclonal antibody of claim 1. 6. A monoclonal antibody which is antibody 64M14. 7. A composition comprising monoclonal antibody 64M14. 8. A method of inhibiting growth of tumor cells, the method comprising contacting the tumor cells with a monoclonal antibody that competes for specific binding to human Jagged 1 with the antibody 64M14 in an amount effective to inhibit tumor cell growth. 9. The method of claim 8 wherein the antibody is conjugated to a cytotoxic moiety. 10. The method of claim 8 further comprising contacting the tumor cells with at least one additional therapeutic agent. 11. The method of claim 10, wherein the additional therapeutic agent is an anti-VEGF antibody. 12. The method of claim 10 wherein the additional therapeutic agent is bevacizumab. 13. The method of claim 8 wherein the tumor cells are from a breast tumor, a colorectal tumor, a lung tumor, a pancreatic tumor, a prostate tumor, or a head and neck tumor. 14. A method of inhibiting growth of tumor cells, the method comprising contacting the tumor cells with monoclonal antibody 64M14.

Details for Patent 8,802,103

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2027-05-15
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.